A practical reference on solid-phase synthesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Triorganosilyl sources have quite variable prices, and the most economical is chlorotrimethylsilane (TMS-Cl), a Direct Process byproduct. The trimethylsilyl ethers are also extremely sensitive to acid hydrolysis (for example silica gel suffices as a proton donator) and are consequently rarely used nowadays as protecting groups.
=== Self-assembly === The self-assembly technique is used to generate peptide nanofibers and peptide amphiphiles. The method was inspired by the natural folding process of amino acid residues to form proteins with unique three-dimensional structures. The self-assembly process of peptide nanofibers involves various driving forces such as hydrophobic interactions, electrostatic forces, hydrogen bonding and van der Waals forces and is influenced by external conditions such as ionic strength and pH.
In addition, it is unlikely that the Israelites overtook the southern Levant by force, according to archaeological evidence. Instead, they branched out of indigenous Canaanite peoples that long inhabited the region, which included Syria, ancient Israel, and the Transjordan region. Their culture was monolatristic, with a primary focus on Yahweh (or El) worship, but after the Babylonian exile, it became monotheistic, with partial influence from Zoroastrianism. The latter decisively separated the Israelites from other Canaanites. The Israelites used the Canaanite script and communicated in a Canaanite language known as Biblical Hebrew. The language's modern descendant is today the only surviving dialect of the Canaanite languages. Genetic studies show that contemporary ethnicities in the Levant were, like Israel, distinguished by their unique cultures, due to their descent from a common ancestral stock. Several theories exist for the origins of historical Israelites. Some believe they descend from raiding groups, itinerant nomads such as Habiru and Shasu or impoverished Canaanites, who were forced to leave wealthy urban areas and live in the highlands. Gary Rendsburg argues that some archaic biblical traditions and other circumstantial evidence point to the Israelites emerging from the Shasu and other seminomadic peoples from the desert regions south of the Levant, later settling in the highlands of Canaan.
Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF) produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.
Sources: en.wikipedia.org
=== The Healing Foundation === In 1998, as Treasurer of the British Association of Plastic, Reconstructive, and Aesthetic Surgeons (BAPRAS), Brough and his fellow Trustees established The Healing Foundation. Building on the groundwork laid by the Phoenix Appeal, The Healing Foundation aimed to advance research into surgical and psychological healing techniques for individuals with disfiguring conditions. Various UK medical membership bodies provided support to The Healing Foundation as Partner Member Organisations. These partnerships bolstered the charity's credibility, networking capabilities, and financial resources.These organisations were BAPRAS, the British Association of Aesthetic Surgeons, the British Psychological Society, the Craniofacial Society of Great Britain and Ireland, the British Burns Association, and the British Society for Surgery of the Hand.
The All-China Federation of Supply and Marketing Cooperatives (Chinese: 中华全国供销合作总社) is a joint organization of the national supply and marketing Cooperatives of China, led by the State Council, with an administrative level of ministerial level. It is a member of the International Cooperative Alliance (ICA).
Water scarcity has been described as endemic, due to overconsumption and pollution. The report states that 10% of the world's population lives in countries with high or critical water stress. Yet over the past 40 years, water consumption has increased by around 1% per year, and is expected to grow at the same rate until 2050. Since 2000, flooding in the tropics has quadrupled, while flooding in northern mid-latitudes has increased by a factor of 2.5. The cost of these floods between 2000 and 2019 was 100,000 deaths and $650 million. Organizations concerned with water protection include the International Water Association (IWA), WaterAid, Water 1st, and the American Water Resources Association. The International Water Management Institute undertakes projects with the aim of using effective water management to reduce poverty. Water related conventions are United Nations Convention to Combat Desertification (UNCCD), International Convention for the Prevention of Pollution from Ships, United Nations Convention on the Law of the Sea and Ramsar Convention. World Day for Water takes place on 22 March and World Oceans Day on 8 June. In 2026, the United Nations declared that humanity had entered the era of "Water bankruptcy" because more than 50% of large lakes have declined since the 1990s, 35% of wetlands have disappeared since 1970, 75% of the world's population live in water-insecure countries, 4 billion people experience water scarcity for at least one month per year, and droughts cost $307 billion per year. It called for policies that match reality rather than past norms.
=== Modified insulin suppression test === Another measure of insulin resistance is the modified insulin suppression test developed by Gerald Reaven at Stanford University. The test correlates well with the euglycemic clamp, with less operator-dependent error. This test has been used to advance the large body of research relating to the metabolic syndrome. Patients initially receive 25 μg of octreotide (Sandostatin) in 5 mL of normal saline over 3 to 5 minutes via intravenous infusion (IV) as an initial bolus, and then, are infused continuously with an intravenous infusion of somatostatin (0.27 μg/m2/min) to suppress endogenous insulin and glucose secretion. Next, insulin and 20% glucose are infused at rates of 32 and 267 mg/m2/min, respectively. Blood glucose is checked at zero, 30, 60, 90, and 120 minutes, and thereafter, every 10 minutes for the last half-hour of the test. These last four values are averaged to determine the steady-state plasma glucose level (SSPG). Subjects with an SSPG greater than 150 mg/dL are considered to be insulin-resistant.
Remoras have their front dorsal fins modified into large suckers with which they cling onto a host animal such as a whale, sea turtle, shark or ray, but this is probably a commensal rather than parasitic arrangement because both remora and host benefit from the removal of ectoparasites and loose flakes of skin. More harmful are the catfish that enter the gill chambers of fish and feed on their blood and tissues. The snubnosed eel, though usually a scavenger, sometimes bores into the flesh of a fish, and has been found inside the heart of a shortfin mako shark. Some species, such as electric eels, can produce powerful electric currents, strong enough to stun prey. Other fish, such as knifefish, generate and sense weak electric fields to detect their prey; they swim with straight backs to avoid distorting their electric fields. These currents are produced by modified muscle or nerve cells.
Sources: en.wikipedia.org
This is seen with the subcutaneous injection of triptans for migraine headache, medroxyprogesterone acetate for contraception, as well as many monoclonal antibodies. In most cases, injection site reactions are self-limiting and resolve on their own after a short time without treatment, and do not require the medication to be discontinued. The administration of vaccines subcutaneously is also associated with injection site reactions. This includes the BCG vaccine which is associated with a specific scar appearance which can be used as evidence of prior vaccination. Other subcutaneous vaccines, many of which are live vaccines including the MMR vaccine and the varicella vaccine, which may cause fever and rash, as well as a feeling of general malaise for a day or two following the vaccination.
== Therapeutic uses of neohormones == Relaxin has been shown to repair and reverse the symptoms associated with scleroderma (an autoimmune condition affecting connective tissues, blood vessels and internal organs) and fibrosis (thickening, hardening or build up of scar tissue). It also aids in the formation of new blood vessels (angiogenesis). This is also beneficial in wound management and healing. Other potential targets include the use of relaxin within human reproduction, such as in the preparation of the cervix for labour and birth and also as a drug target for breast cancer treatment although much more research is required in this area. Oxytocin is important for many different biological processes including social, maternal and sexual behaviours, pregnancy, milk production, and ejaculation. Agonists and antagonists of oxytocin – development of drugs that can utilise the receptor binding activity of oxytocin is an important therapeutic target as this could be applied to a range of conditions. Oxytocin plays a role in cell proliferation and differentiation in different ways depending on where it is in the body. Understanding the underlying pathways for different localities could help with development of cancer therapies.
Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication attempts to improve sexual desire, increase the number of satisfying sexual events, and decrease the distress associated with low sexual desire. The most common side effects are dizziness, sleepiness, nausea, difficulty falling asleep or staying asleep and dry mouth. Development by Boehringer Ingelheim was halted in October 2010, following a negative evaluation by the US Food and Drug Administration (FDA). The rights to the drug were then transferred to Sprout Pharmaceuticals, which achieved approval of the drug by the US FDA in August 2015. Addyi is approved for medical use in the United States for premenopausal women with hypoactive sexual desire disorder and in Canada for premenopausal and postmenopausal women with hypoactive sexual desire disorder. Hypoactive sexual desire disorder was recognized as a distinct sexual function disorder for more than 30 years, but was removed from the Diagnostic and Statistical Manual of Mental Disorders in 2013, and replaced with a new diagnosis called female sexual interest/arousal disorder (FSIAD).
In October 2018, Reitan Convenience, a division of Reitan AS, acquired the chain, with the founding team remaining in management. Soon after, the brand was shortened to Caffeine and integrated into the group's wider convenience formats. The concept expanded beyond the Baltics, with cafés opening in Oslo and Copenhagen. In 2022 the chain switched all Baltic outlets to serving only certified organic beans, becoming the first in the region to do so.By 2025 Caffeine operated more than 100 cafés in Lithuania, including a new drive-through and charging hub in Varėna. The chain also ran 27 cafés in Latvia and 12 in Estonia.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.